BenjaminJesseAnsellMD

PubMed

• 464 citations
  Dysfunctional HDL and atherosclerotic cardiovascular disease
  Robert S. Rosenson, H. Bryan Brewer, Benjamin J. Ansell, Philip J. Barter, M. John Chapman, Jay W. Heinecke, Anatol Kontush, Alan R. Tall, Nancy R. Webb> ;Nature Reviews. Cardiology. 2016 Jan 1
• 4 citations
  JCL roundtable: HDL in the primary care setting.
  W. Virgil Brown, Benjamin J. Ansell, Rachel H. Mackey, Peter P. Toth> ;Journal of Clinical Lipidology. 2014 Jul 1
• 19 citations
  Clinical decisions. The guidelines battle on starting statins.
  Ralph B. D'Agostino, Benjamin J. Ansell, Samia Mora, Harlan M. Krumholz> ;The New England Journal of Medicine. 2014 Apr 24
• 168 citations
  Translation of High-Density Lipoprotein Function Into Clinical Practice Current Prospects and Future Challenges
  Robert S. Rosenson, H. Bryan Brewer, Benjamin J. Ansell, Philip J. Barter, M. John Chapman, Jay W. Heinecke, Anatol Kontush, Alan R. Tall, Nancy R. Webb> ;Circulation. 2013 Sep 10
• 11 citations
  Neisseria lactamica Arthritis and Septicemia Complicating Myeloma
  Richard J. Everts, David J. Speers, Sean T. George, Benjamin J. Ansell, Harin Karunajeewa, Rosanna D. Ramos> ;Journal of Clinical Microbiology. 2010 Jun 1
• A review of trials evaluating nonstatin lipid-lowering therapies
  Benjamin J. Ansell> ;Current Atherosclerosis Reports. 2009 Jan 1
• 75 citations
  Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus...
  Bevra H. Hahn, Jennifer M. Grossman, Benjamin J. Ansell, Brian J. Skaggs, Maureen McMahon> ;Arthritis Research & Therapy. 2008 Aug 29
• 1 citations
  Hyperlipidaemia and cardiovascular disease.
  Benjamin J. Ansell> ;Current Opinion in Lipidology. 2008 Aug 1
• 13 citations
  Not getting to goal: the clinical costs of noncompliance.
  Benjamin J. Ansell> ;Journal of Managed Care Pharmacy. 2008 Jul 1
• 29 citations
  Targeting the anti-inflammatory effects of high-density lipoprotein.
  Benjamin J. Ansell> ;The American Journal of Cardiology. 2007 Dec 3
• 16 citations
  The two faces of the 'good' cholesterol.
  Benjamin J. Ansell> ;Cleveland Clinic Journal of Medicine. 2007 Oct 1
• 345 citations
  High-density lipoprotein as a therapeutic target: a systematic review.
  Inder M. Singh, Mehdi H. Shishehbor, Benjamin J. Ansell> ;JAMA. 2007 Aug 15
• 218 citations
  The paradox of dysfunctional high-density lipoprotein.
  Benjamin J. Ansell, Gregg C. Fonarow, Alan M. Fogelman> ;Current Opinion in Lipidology. 2007 Aug 1
• 82 citations
  Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.
  Christina Charles-Schoeman, Dinesh Khanna, Daniel E. Furst, Maureen McMahon, Srinivasa T. Reddy, Alan M. Fogelman, Harold E. Paulus, Grace S. Park, Timothy Gong, Benja...> ;The Journal of Rheumatology. 2007 Jul 1
• 9 citations
  HDL function as a target of lipid-modifying therapy.
  Karol E. Watson, Benjamin J. Ansell, Andrew D. Watson, Gregg C. Fonarow> ;Reviews in Cardiovascular Medicine. 2007 Jan 1
• 7 citations
  The potential for CETP inhibition to reduce cardiovascular disease risk.
  Benjamin J. Ansell, FD Richard Hobbs> ;Current Medical Research and Opinion. 2006 Nov 2
• 27 citations
  Modifying the anti-inflammatory effects of high-density lipoprotein
  Benjamin J. Ansell, Gregg C. Fonarow, Mohamad Navab, Alan M. Fogelman> ;Current Atherosclerosis Reports. 2007 Jan 1
• 30 citations
  Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents : Results of a national survey
  Benjamin J. Ansell, Gregg C. Fonarow, Kevin C. Maki, Mary R. Dicklin, Margie Bell, Michael H. Davidson> ;American Heart Journal. 2006 Nov 1
• 58 citations
  High-density lipoprotein: is it always atheroprotective?
  Benjamin J. Ansell, Gregg C. Fonarow, Alan M. Fogelman> ;Current Atherosclerosis Reports. 2006 Sep 1
• 179 citations
  Mechanisms of Disease: proatherogenic HDL—an evolving field
  Mohamad Navab, Gattadahalli M. Anantharamaiah, Srinivasa T. Reddy, Brian J. Van Lenten, Benjamin J. Ansell, Alan M. Fogelman> ;Nature Clinical Practice. Endocrinology & Metabolism. 2006 Sep 1
• 197 citations
  High-density lipoprotein function recent advances.
  Benjamin J. Ansell, Karol E. Watson, Alan M. Fogelman, Mohamad Navab, Gregg C. Fonarow> ;Journal of the American College of Cardiology. 2005 Nov 15
• 23 citations
  Evidence for a combined approach to the management of hypertension and dyslipidemia
  Benjamin J. Ansell> ;American Journal of Hypertension. 2005 Sep 1
• 224 citations
  Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under t...
  Michael H. Davidson, Kevin C. Maki, Thomas A. Pearson, Richard C. Pasternak, Prakash Deedwania, James M. McKenney, Gregg C. Fonarow, David J. Maron, Benjamin J. Ansell...> ;The American Journal of Cardiology. 2005 Aug 15
• 200 citations
  Apolipoprotein A-I Mimetic Peptides
  Mohamad Navab, Gattadahalli M. Anantharamaiah, Srinivasa T. Reddy, Susan Hama, Greg Hough, Victor Grijalva, Nicholas Yu, Benjamin J. Ansell, Geeta Datta, David W. Garb...> ;Arteriosclerosis, Thrombosis, and Vascular Biology. 2005 Jul 1
• 10 citations
  Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
  Benjamin J. Ansell> ;Current Atherosclerosis Reports. 2005 Feb 1
• Join now to see all

Journal Articles

• Clinical decisions The guidelines battle on starting statins  
  D’Agostino RB, Ansell BJ, Mora S, Krumholz HM, New England Journal of Medicine, 1/1/2014
• Translation of HDL Function into Clinical Practice: Current Prospects and Future Challenges  
  Rosenson RS, Brewer HB, Ansell BJ, Barter P, Chapman MJ, Heinecke J, Kontush A, Tall AR, Webb N, Circulation, 1/1/2013
• Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory HDL and accelerated atherosclerosis in rheumatic diseases  
  Hahn BS, Grossman J, Ansell BJ, Skaggs B, McMahon M, Arthritis Research and Therap, 1/1/2008
• Effects of high-dose atorvastatin on high-density lipoproteins’ anti-inflammatory properties and disease activity in patients with rheumatoid arthritis  
  Charles-Schoeman CM, Khanna D, Furst DE, McMahon M, Navab M, Reddy S, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ, Journal of Rheumatology, 1/1/2007
• The two faces of HDL  
  Ansell BJ, Cleve Clin J Med, 1/1/2007
• Targeting the anti-inflammatory effects of high-density lipoprotein  
  Ansell BJ, American Journal of Cardiology, 1/1/2007
• The paradox of dysfunctional HDL  
  Ansell BJ, Fonarow GC, Fogelman AM, Current Opinion in Lipidology, 1/1/2007
• C-Reactive Protein Not a Reliable Marker for CV Risk in the Elderly Reply to letter to Editor  
  Ansell BJ, Resident & Staff Physician, 1/1/2006
• How to get your high-risk patients to the new NCEP goals  
  Ansell BJ, Patient Care, 1/1/2006
• Proatherogenic HDL - an evolving field  
  Navab, MN, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM, Nature Clin Pract Endo Metab, 1/1/2006
• Is aggressive or moderate lipid lowering more effective in slowing vascular calcification in postmenopausal women?  
  Watson KE, Ansell BJ, Fonarow GC, Nat Clin Pract Cardiovasc Med, 1/1/2006
• Reduced Treatment Success in Lipid Management Among Women with Coronary Heart Disease or Risk Equivalents: Results of a National Survey  
  Ansell BJ, Fonarow GC, Maki KC, Dicklin, MR, Bell M, Davidson MH for the NEPTUNE II Steering Committee, Amer Heart J, 1/1/2006
• Results of the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey: Implications for Treatment Under the Revised...  
  Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Stone NJ, Ballantyne CM, American Journal of Cardiology, 1/1/2005
• The double jeopardy of HDL  
  Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Grijalva VR, Kamranpour N, Wagner AC, Mehrabian M, Shaposhnik Z, Lusis AJ, and Fogelma..., Annals of Medicine, 1/1/2005
• Apolipoprotein A-I Mimetic Peptides  
  Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM, Arteriosclerosis, Thrombosis, and Vascular Biology, 1/1/2005
• Evidence for a combined approach to the management of hypertension and dyslipidemia  
  Ansell BJ, American Journal of Hypertension, 1/1/2005
• HDL: Recent Advances  
  Ansell BJ, Navab M, Watson KE, Fogelman, AM, Fonarow GC, Journal of the American College of Cardiology, 1/1/2005
• The Oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL  
  Navab M, Ananthramaiah GM, Reddy, ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner J, Lusis AJ, Fogelman, AM, Journal of Lipid Research, 1/1/2004
• Anti-inflammatory properties of HDL  
  Ansell BJ, Navab M, Watson KE, Fonarow, GC, Fogelman AM, Reviews in Endocrine and Metabolic Disorders, 1/1/2004
• Metabolic syndrome patients have higher plasma lipid hydroperoxides and more pro-inflammatory HDL than dyslipidemic control subjects, even with comparable levels of HD...  
  Watson KE, Hama S, Fonarow GC, Ansell BJ, Navab M, Fogelman AM, Circulation, 1/1/2004
• The metabolic syndrome in postmenopausal women  
  Ansell BJ, Contemporary OB/Gyn, 1/1/2003
• The inflammatory/anti-inflammatory properties of HDL distinguish patients from controls better than HDL-cholesterol, and are improved by simvastatin therapy  
  Ansell BJ, Navab N, Hama S, Kamranpour N, Fonarow G, Hough G, Mottahedeh R, Dave R, Reddy ST, Fogelman, AM, Circulation, 1/1/2003
• The metabolic syndrome: an interplay of multiple subtle cardiovascular risk factors  
  Ansell BJ, Journal of Clinical Outcomes Management, 1/1/2002
• Improvements in current approaches to lipid-lowering  
  Ansell BJ, Am Fam Physician, 1/1/2002
• Reassessment of National Cholesterol Education Program Adult Treatment Panel III Guidelines: one year later  
  Ansell BJ, Waters DD, Am J Cardiol, 1/1/2002
• Join now to see all

Books/Book Chapters

• Clinical Preventive Medicine 
  Chapter: “Asthma and Allergic Disorders” 
  Ansell BJ, Serio KJEditors: Lang RS, Hensrud DD.AMA Press, Chicago, IL2004
• Principles and Clinical Practice 
  Chapter: “Hyperlipidemia” 
  Ansell BJEditors: Pregler JP, DeCherney AH.BC Decker, New York2002
• Hyperlipidemia. 
  Ansell BJ.Editors: Pregler JP, DeCherney AH.Women’s Health: Principles and Clinical Practice., New York
• Asthma and Allergic Disorders. 
  Ansell BJ, Serio KJ.Editors: Lang RS, Hensrud DD.Clinical Preventive Medicine, Chicago
• Join now to see all

Abstracts/Posters

• Adding D-4F at nanomolar concentrations to human plasma rapidly remodels HDL reduces lipid hydroperoxide content, and converts HDL from pro-inflammatory to anti-inflam...
  Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Watson KE, Datta G, Palgunachari MN, Fogelman AM, ACC Scientific Sessions, 1/1/2005
• Effects of High-Dose Atorvastatin on HDL Anti-inflammatory/Pro-inflammatory Function and Disease Activity in Patients with Rheumatoid Arthritis. Results of the Statin ...
  Charles C, Khanna D, Navab M, Reddy S, Fogelman AM, Furst DE, Paulus HE, Park GS, Ansell BJ, Abstract at American College of Cardiology Scientific Sessions, Atlanta, GA, 1/1/2005
• The inflammatory/anti-inflammatory properties of HDL distinguish patients from controls better than HDL-cholesterol, and are improved by simvastatin therapy.
  Ansell BJ, Navab N, Hama S, Kamranpour N, Fonarow G, Hough G, Mottahedeh R, Dave R, Reddy ST, Fogelman, AM., Circulation
• Dispelling myths about cholesterol management: an evidence-based approach.
  Ansell BJ., Patient Care.
• Stroke reduction.
  Ansell BJ., Patient Care.
• Colesevelam.
  Ansell BJ., Am J Cardiovasc Drugs.
• Optimal first line therapy to achieve lipid targets in diabetes.
  Ansell BJ., Arch Int Med.
• The metabolic syndrome: an interplay of multiple subtle cardiovascular risk factors.
  Ansell BJ., Journal of Clinical Outcomes Management.
• Adopting the New National Cholesterol Education Program guidelines into clinical practice.
  Ansell BJ. Earlywine KS., Physician Assist.
• Lipid lowering therapy. What the new NCEP guidelines recommend.
  Ansell BJ., Emerg Med.
• Should we be recommending a statin for most older Americans?
  Ansell BJ., Clinical Geriatrics
• The metabolic syndrome in postmenopausal women.
  Ansell BJ., Contemporary OB/Gyn
• HDL: Recent Advances.
  Ansell BJ, Navab M, Watson KE, Fogelman, AM, Fonarow GC., Journal of the American College of Cardiology.
• C-Reactive Protein Not a Reliable Marker for CV Risk in the Elderly.
  Ansell BJ., Resident & Staff Physician
• How to get your high-risk patients to the new NCEP goals.
  Ansell BJ., Patient Care.
• Is aggressive or moderate lipid lowering more effective in slowing vascular calcification in postmenopausal women?
  Watson KE, Ansell BJ, Fonarow GC., Nat Clin Pract Cardiovasc Med.
• Modifying HDL’s anti-inflammatory properties.
  Ansell BJ, Fonarow GC, Fogelman AM., Current Atherosclerosis Reports.
• The two faces of HDL.
  Ansell BJ., Cleve Clin J Med.
• Management of Low HDL.
  Ansell BJ., National Lipid Association
• Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory HDL and accelerated atherosclerosis in rheumatic diseases.
  Hahn BS, Grossman J, Ansell BJ, Skaggs B, McMahon M., Arthritis Research and Therapy.
• Nonstatin drugs.
  Ansell BJ., Current Atherosclerosis Reports.
• The inflammatory/anti-inflammatory properties of human HDL are inversely related to the ability of the HDL to promote cholesterol efflux from human monocyte/macrophages.
  Ansell BJ, Grijalva V, Navab M, Hama S, Hough G, Reddy ST, Fogelman AM., AHA
• Metabolic syndrome patients have higher plasma lipid hydroperoxides and more pro-inflammatory HDL than dyslipidemic control subjects, even with comparable levels of HD...
  Watson KE, Hama S, Fonarow GC, Ansell BJ, Navab M, Fogelman AM., Circulation
• Adding D-4F at nanomolar concentrations to human plasma rapidly remodels HDL reduces lipid hydroperoxide content, and converts HDL from pro-inflammatory to anti-inflam...
  Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Watson KE, Datta G, Palgunachari MN, Fogelman AM., ACC Scientific Sessions.
• Join now to see all

Lectures

• Lower Together: LDL-C Risk Hassle Cost 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• “Prevention of CVD, Perspectives on Lipid Guidelines” 
  6/1/2014
• HDL: State of the Lipoprotein 
  Maui, HI - 4/1/2014
• “Charting A Career In Medicine” 
  4/1/2014
• “Comprehensive CVD Risk Reduction in Type 2 Diabetes” 
  1/1/2014
• Management of Hypertension 
  8/1/2013
• “Dysfunctional HDL in Cardiovascular and Inflammatory Diseases” 
  Washington, DC - 2/1/2013
• “LDL-C and Cardiovascular Risk Reduction in Statin-Intolerant Patients” 
  Los Angeles, CA - 11/1/2012
• “High-Density Lipoproteins: Anti-Atherogenic Functions and Targets” 
  Boston, MA - 10/1/2012
• “Management of the Low HDL Patient” 
  Newport Beach, CA - 10/1/2012
• Translation of Clinical Science Slide Series (Chair: Current Therapies) 
  10/1/2012
• HDL Master’s Course “HDL: Current Therapies” 
  Charlotte, NC - 9/1/2012
• “CETP Inhibition: Promise Unrealized” 
  9/1/2012
• “Lipid Management (I)” 
  8/1/2012
• “HDL: Clinical Trials Update (Grand Rounds)” 
  Dallas, TX - 5/1/2012
• HDL Master’s Course “HDL and Lifestyle” 
  Scottsdale, AZ - 5/1/2012
• “CETP: Will Its Inhibition Reverse Atherosclerosis” 
  5/1/2012
• “The Changing Landscape of HDL” 
  Anaheim, CA - 4/1/2012
• “HDL – Should We Be ‘AIMing HIGH’?” 
  San Diego, CA - 3/1/2012
• “Lifestyle Influences on HDL and HDL-Cholesterol” 
  San Diego, CA - 3/1/2012
• “Determining Clinically Relevant Measures of HDL Function” 
  New York, NY - 2/1/2012
• “Preparing for the Instant” 
  Los Angeles, CA - 11/1/2011
• "The Digital Doctor: How Technology Can Keep You Healthy” 
  5/1/2011
• “HDL Function in CVD and Other Inflammatory Conditions” 
  Washington, DC - 2/1/2011
• “Science and Fiction in Health and the Media” 
  2/1/2011
• Join now to see all

Other

• A review of trials evaluating nonstatin lipid-lowering therapies. 
  Ansell BJ, Current Atherosclerosis Reports
  1/1/2009
• Nonstatin drugs [Section Editor]. 
  Ansell BJ, Current Atherosclerosis Reports
  1/1/2009
• Modifying HDL’s anti-inflammatory properties. 
  Ansell BJ, Fonarow GC, Fogelman AM, Current Atherosclerosis Reports
  1/1/2007
• HDL: Is it always atheroprotective? 
  Ansell BJ, Fonarow GC, Fogelman AM, Current Atherosclerosis Reports
  1/1/2006
• Rationale for combination therapy with statins in the treatment of dyslipidemia. 
  Ansell BJ, Current Atherosclerosis Reports
  1/1/2005
• “The New Heart Failure Guidelines: Focus on Prevention” 
  Ansell BJ; Gregg Fonarow, MD & Karol Watson, MD, CME Audiotape
  11/1/2002
• “Treating the Diabetic Patient at Risk for CHD” 
  Ansell BJ, UCSD School of Medicine CD-ROM
  6/1/2000
• “Practical Cholesterol Management in a Primary Care Setting: Using Lipid Lowering to Improve and Save the Lives of Your Patients” 
  Ansell BJ, CME Audio Tape
  12/1/1998
• Fearing one fate, women ignore a killer. 
  Ansell BJ., New York Times
• When “health” supplements may do harm. 
  Ansell BJ., New York Times.
• NLA position statement on AIM-HIGH results. 
  Ansell BJ, Brown WV
  http://lipid.org/pages/statement.php
• Join now to see all